DE2542794C2 - Molekülverbindungen aus Allantoin und Salzen der 2-Pyrrolidon-5-carbonsäure sowie Verfahren zu ihrer Herstellung - Google Patents
Molekülverbindungen aus Allantoin und Salzen der 2-Pyrrolidon-5-carbonsäure sowie Verfahren zu ihrer HerstellungInfo
- Publication number
- DE2542794C2 DE2542794C2 DE2542794A DE2542794A DE2542794C2 DE 2542794 C2 DE2542794 C2 DE 2542794C2 DE 2542794 A DE2542794 A DE 2542794A DE 2542794 A DE2542794 A DE 2542794A DE 2542794 C2 DE2542794 C2 DE 2542794C2
- Authority
- DE
- Germany
- Prior art keywords
- allantoin
- pca
- sodium
- salts
- pyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 title claims description 100
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 title claims description 49
- 229960000458 allantoin Drugs 0.000 title claims description 49
- 150000003839 salts Chemical class 0.000 title claims description 26
- 150000001875 compounds Chemical class 0.000 title claims description 19
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical class OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 title claims description 8
- 238000000034 method Methods 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title description 4
- 239000011734 sodium Substances 0.000 description 23
- 239000013078 crystal Substances 0.000 description 22
- 229910052708 sodium Inorganic materials 0.000 description 21
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 14
- 239000011575 calcium Substances 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 229910052799 carbon Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 238000000921 elemental analysis Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 150000002431 hydrogen Chemical class 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 4
- 239000000920 calcium hydroxide Substances 0.000 description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 101100353526 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pca-2 gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000035984 keratolysis Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP49109509A JPS5136453A (en) | 1974-09-25 | 1974-09-25 | Arantointo 22 piroridon 55 karubonsanen no bunshikagobutsu no seizoho |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2542794A1 DE2542794A1 (de) | 1976-04-15 |
| DE2542794C2 true DE2542794C2 (de) | 1982-11-18 |
Family
ID=14512055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2542794A Expired DE2542794C2 (de) | 1974-09-25 | 1975-09-25 | Molekülverbindungen aus Allantoin und Salzen der 2-Pyrrolidon-5-carbonsäure sowie Verfahren zu ihrer Herstellung |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4025525A (esLanguage) |
| JP (1) | JPS5136453A (esLanguage) |
| DE (1) | DE2542794C2 (esLanguage) |
| FR (1) | FR2285874A1 (esLanguage) |
| GB (1) | GB1500415A (esLanguage) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH629230A5 (de) * | 1977-11-04 | 1982-04-15 | Ciba Geigy Ag | Verfahren zur herstellung von metallsalz-aminkomplexen und ihre verwendung. |
| CH629485A5 (de) * | 1977-11-04 | 1982-04-30 | Ciba Geigy Ag | Verfahren zur herstellung von pyrrolidoncarbonsaeure-metall-amin-komplexen. |
| US4181804A (en) * | 1979-01-10 | 1980-01-01 | Carroll Products, Inc. | Allantoin urocanic acid complexes |
| JPS57199953U (esLanguage) * | 1981-06-17 | 1982-12-18 | ||
| US4465663A (en) * | 1981-07-27 | 1984-08-14 | Basf Wyandotte Corporation | Polyoxybutylene-polyoxyethylene aqueous gels |
| KR100502597B1 (ko) | 1996-12-27 | 2005-07-22 | 폴리플라스틱스 가부시키가이샤 | 폴리아세탈 수지 조성물 및 성형품 |
| JP4681132B2 (ja) * | 2001-01-29 | 2011-05-11 | 味の素株式会社 | 一酸化窒素合成酵素産生促進剤および化粧料若しくは医薬組成物 |
| US20140135372A1 (en) | 2010-02-02 | 2014-05-15 | Elliott Farber | Compositions and methods of treatment of inflammatory skin conditions using allantoin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3107252A (en) * | 1959-12-01 | 1963-10-15 | Irwin I Lubowe | Allantoin salt |
| US3275643A (en) * | 1963-07-19 | 1966-09-27 | Irwin I Lubowe | Allantoin-pantothenate compounds |
| GB1091179A (en) | 1965-04-07 | 1967-11-15 | Irwin Irville Lubowe | Allantoin complexes and processes for synthesising them |
| US3290324A (en) * | 1965-04-16 | 1966-12-06 | Irwin I Lubowe | Allantoin biotin compositions |
| US3305557A (en) * | 1965-04-16 | 1967-02-21 | Irwin I Lubowe | Allantoin p-aminobenzoic acid complexes |
-
1974
- 1974-09-25 JP JP49109509A patent/JPS5136453A/ja active Granted
-
1975
- 1975-09-16 US US05/613,913 patent/US4025525A/en not_active Expired - Lifetime
- 1975-09-24 GB GB39117/75A patent/GB1500415A/en not_active Expired
- 1975-09-25 FR FR7529367A patent/FR2285874A1/fr active Granted
- 1975-09-25 DE DE2542794A patent/DE2542794C2/de not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| US4025525A (en) | 1977-05-24 |
| JPS5136453A (en) | 1976-03-27 |
| FR2285874A1 (fr) | 1976-04-23 |
| FR2285874B1 (esLanguage) | 1978-09-08 |
| GB1500415A (en) | 1978-02-08 |
| JPS5337347B2 (esLanguage) | 1978-10-07 |
| DE2542794A1 (de) | 1976-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3686362T2 (de) | Verfahren zur behandlung von magen-darmstoerungen. | |
| DE2605386C2 (de) | Aluminium-Zirkon-Komplexe zur Verwendung als Antitranspirantien | |
| DE3533007C2 (esLanguage) | ||
| DE3930638A1 (de) | Verbindungen gegen uebermaessiges schwitzen | |
| DE3314150C2 (de) | Zahnzement, enthaltend Tanninderivate | |
| DE2542794C2 (de) | Molekülverbindungen aus Allantoin und Salzen der 2-Pyrrolidon-5-carbonsäure sowie Verfahren zu ihrer Herstellung | |
| DE2260536C3 (de) | MolekiileinschluBverbindungen aus einem Silberalkanolammin-Komplex und beta-Cycloheptaamylose, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2431483C3 (de) | Verfahren zur Herstellung von Alkali- oder Ammoniumsalzen von Insulin | |
| DE2617402C2 (esLanguage) | ||
| DE3152555C2 (esLanguage) | ||
| DE2725246C2 (esLanguage) | ||
| DE69804597T2 (de) | Salbe zur behandlung von verbrennungen und anderen hautkrankheiten | |
| DE2322699C2 (de) | Quecksilberfreie Diuretika | |
| DE2327687A1 (de) | Antiseptisches mittel | |
| DE1568807C3 (de) | Verfahren zur Herstellung von aktiven Calciumsuccinaten in eis-Form | |
| DE3049123C2 (de) | Fettsaeureester von 4-isopropyltropolon und hautverschoenerndes, kosmetisches mittel | |
| DE1768655A1 (de) | Neue Salze der N-Carbamylglutaminsaeure und der N-Carbamylasparaginsaeure | |
| DE3840744C2 (de) | Aktivator für Osteoblasten | |
| DE147580C (esLanguage) | ||
| DE68916912T2 (de) | Zinncysteat, dessen Herstellung und dessen pharmazeutische und kosmetische Verwendungen. | |
| DE713257C (de) | Desinfektionsmittel | |
| DE3344891C2 (esLanguage) | ||
| EP0098475A2 (de) | Pharmazeutische Zusammensetzung, ihre Herstellung und Verwendung | |
| DE532536C (de) | Verfahren zur Herstellung von Sulfosalicylsaeure-Verbindungen des Chinins | |
| DE2901914A1 (de) | Neues derivat der n-acetyl-amino-6- capronsaeure, verfahren zu dessen herstellung und arzneimittel unter verwendung des derivats als wirkstoff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination | ||
| 8339 | Ceased/non-payment of the annual fee |